Home
overview

The growing threat of bacterial resistance has been underscored by governments, medical personnel and academia alike. These threats have been compared to that of terrorism by the Chief Medical Officer of the UK. Following from last year's very successful event, SMi is proud to present its 16th Annual Conference on Superbugs and Superdrugs.

This event is a well established one and is very famous in its niche market. This year’s focus will be on how to address this ever increasing bacterial resistance. The conference will also address the main challenges that pharmaceutical companies are currently facing in terms of funding and low unit price of antibiotics and will look at how these companies can go into partnerships and have access to funds and wider expertise

This exciting event will bring together industry leaders from big pharma companies, biotech companies, regulatory agencies and academia to discuss the latest development in the antibacterial market. This unique conference will present attendees with a complete view into the latest research in combating multi-drug resistance.

Key areas to be discussed in this year’s conference are:

• Research and development in neglected diseases
• Horizons for antimicrobial resistance (AMR)
• Controlling the use of new antibiotics
• Public/private partnerships and how you can benefit from it
• The latest treatment for Hepatitis C
• Antibody based strategies
• Nanoparticles approach to treat Gram-Positive and Gram-Negative pathogens
• Regulatory aspects of for new antimicrobials
• Alternative models for tackling antimicrobial resistance

The conference will be made up of a number of presentations and case studies from key opinion leaders and updates on their latest research projects and real life success stories for all attendees to learn from.

March 2013 testimonials include:

"Very well organised conference" - GSK
"Good level of quality" - Janssen
"Very good and engaging speakers" - Merck
"Good topics, mix of basic research and clinical development and perspectives" - J&J

 

 

 

 

  • Discover the latest Public/Private Partnerships to combat antimicrobial resistance both in the US and in Europe
  • Consider antibody based strategies as a new method to tackle antimicrobial resistance
  • Discuss the different therapeutic approaches in fighting Clostridium Difficile Infections, Hepatitis C, Pseudomonas aeruginosa infections and Staphylococci infections
  • Learn about hot topics which include antimicrobial stewardship, nanoparticulate oligonucleotide antibacterials and alternative models for tackling antimicrobial resistance
     

This conference is a must-attend event for all those responsible for research, medical microbiology, antimicrobial therapeutics, clinical development and business development, including;

• Chief Scientific Officers
• Senior Vice Presidents
• Chief Medical Officers
• Research Scientists
• Clinical Microbiologists
• R&D Project Managers
 

 • Heads of Anti-Infectives Discovery
• Clinical Trials Managers
• Principal Scientists
• Senior Vice Presidents of R&D
• Business Development Managers
• Product Managers

March 2013 delegates included:

ADMISSIONS; AFFILOGIC; Affinium Pharmaceuticals; Anacor Pharmaceuticals Inc; Antabio; Aquapharm Biodiscovery; Astellas Pharma Europe; AuraSense Therapeutics LLC; Basilea Pharmaceutica Ltd; Biomedical Advanced Research and Development Authority; Biopharm Insight; Biota; Center For Anti-Infective Agents; D S T L Chemical And Biological Sciences; Da Volterra; EFPIA; Euprotec; European Commision; Evolva SA; Ferrer Internacional; Fidelta; Johnson and Johnson Pharmaceutical Research and Development; Kuwait University; KWS BioTest Ltd; Menarini; Nosopharm; Novartis Institutes for Biomedical Research Inc.; Phico Therapeutics; Rib-X Pharmaceuticals; Sanofi; St George's, University of London; Summit; The Medicines Company; Thomson Reuters; Tibotec; TranScrip Partners; University of North Texas Health Science Center; Vertex Pharmaceuticals;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

9:10 Superdrugs for Superbugs

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

  • What will it take to ensure the appropriate supply of new antibiotics for the treatment of infections caused by MDR pathogens?
  • Big pharma, small pharma and other stakeholders
  • What needs to happen now and later?
  • When do we need these treatments?
  • Has time run out?
  • 9:50 Economic incentives for new antibiotics

    Chris Hoyle

    Chris Hoyle, Economist, Office for Health Economics

  • Impact of incentives on commercial viability of new antibiotics
  • Public-Private Partnerships, regulatory and off-setting the cost of uncertainty
  • Commercial models for new antibiotics
  • 10:30 Morning Coffee

    11:00 A new class of Gram negative antibiotics

    Daniel Obrecht

    Daniel Obrecht, CSO and Co-Founder, Polyphor Ltd

  • Derived from Polyphor's proprietary Protein Epitope Mimetics (PEM) Technology
  • Novel mode of action also active against MDR strains
  • Lead compound POL7080 in Phase II specifically targeting Pseudomonas infections
  • Antibiotic discovery program with activity against ESKAPE pathogens
  • 11:40 Research and development in neglected diseases

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • Overview and clinical relevance
  • Current therpies and issues
  • why pursue reserch or neglected diseases
  • New research efforts and tretment options
  • Can GAIN, IMI and/or BARDA incentivize efforts?
  • 12:20 Novel antiseptic polypeptide (Aspidasept®) targeting susceptible and resistant bacteria and their pathogenicity factors

    Klaus Brandenburg

    Klaus Brandenburg, CSO and Senior Scientist, Brandenburg Antiinfektiva GmbH and Forschungszentrum Borstel

  • Aspidasept
  • Sepsis
  • Endotoxin
  • MRSA
  • Lipoprotein
  • 13:00 Networking Lunch

    14:10 Horizons for AMR

  • State of play of implementation of the EU Action Plan on AMR
  • Horizon 2020 and AMR
  • Line Matthiessen

    Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision

    14:50 Public/private partnerships and how you can benefit from it

    James Anderson

    James Anderson, European Partnerships Director, GSK

  • Stimulating new antibiotic research through public/private partnerships
  • Improving current and future clinical trials through ppp projects
  • Sharing expertise between public and private partners
  • 15:30 Afternoon Tea

    16:00 Working with BARDA

    Joseph Larsen

    Joseph Larsen, Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority

  • Overview of BARDA
  • The strategic way of solving critical health issues
  • Current research projects with BARDA
  • BARDA's support in new broad spectrum antibiotic research
  • 16:40 Panel discussion: Considering different sources of funding antibiotic R&D

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    Joseph Larsen

    Joseph Larsen, Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority

    James Anderson

    James Anderson, European Partnerships Director, GSK

    Line Matthiessen

    Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision

    17:40 Chairman's Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    9:10 The latest treatment for Hepatitis C: challenges and opportunities

    Pierre  Raboisson

    Pierre Raboisson, Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development

  • An estimated 3% of the world's population, more than 170 million people, are infected by the hepatitis C Virus (HCV). Most infections become chronic, which is a condition that is incurable in many patients, leading to chrrhosis, end-stage liver disease and hepato cellular carcinoma.
  • Protease inhibitor (boceprevir, telaprevir and simeprevir) based triple therapy with pegylated interferon and ribavirin marked the beginning of a new era in HCV therapy for genotype 1 patients.
  • New direct-acting antivirals (DAAs) are being developed and will reach the market in the coming months and years, making the treatment of HCV a rapidly evolving field.
  • New interferon-free combination treatment regimens are expected to emerge soon. These novel options to treat HCV infection with DAAs in IFN-free regimens will be discussed.
  • 9:50 Preclinical development of novel and potent nanoparticulate oligonucleotide antibacterials to treat Gram-positive and Gram-negative pathogens

    Michael McArthur

    Michael McArthur, Chief Scientific Officer, Procarta Biosystems Ltd.

  • Novel nanoparticles that deliver to both Gram-positive and Gram-negative pathogens
  • Oligonucleotide therapeutics inhibit transcription factors to block expression of essential bacterial genes
  • High potency in vitro and in vivo against restraint strains
  • Therapies can be designed rapidly, on the basis of sequence, to counter emerging strains
  • 10:30 Morning Coffee

    11:00 Clostridium difficile infections: Challenges and opportunities

    Richard Vickers

    Richard Vickers, Associate Director, R&D, Summit

  • Update on epidemiology
  • Current approaches and challenges to treatment
  • Clinical development pipeline
  • Alternative therapeutic approaches
  • 11:40 Case Study: The activity of BAL30072 against multidrug resistant Gram-negative bacilli

  • Mechanism of B-lactam resistance in Gram negative bacteria
  • Engineering B-lactamase stability into novel compounds
  • Accelerating influx and avoiding efflux
  • Defining appropriate susceptibility test conditions
  • Malcolm Page

    Malcolm Page, Head of Biology, Basilea Pharmaceutica Ltd

    12:20 Networking Lunch

    13:30 What can we do beyond antibiotics to fight Staphylococci infections?

    Michael Mourez

    Michael Mourez, Therapeutic Area Leader, Sanofi-Aventis

  • The Infectious Diseases in Sanofi will be presented, showing a broad spectrum of therapeutic and propylatic approaches at various phases of the R&D pipeline.
  • The burden of Straphylococci in severe infections will be shortly presented, emphasizing the need to prevent those infections, mitigate the deleterious effects of virulence factors during acute infections, potentiate existing antibiotics in persistent infections
  • A human mAb targeting a conserved exopolysaccharide of Staphylococci will be presented, with the preclinical and clinical data obtained to far in an effort to prevent severe infections in Intensive Care Units.
  • Additional preclinical approaches targeting Staphylococci will be presented
  • 14:10 A Novel Bispecific Antibody for Treating Pseudomonas aeruginosa Infections

    Ralph Minter

    Ralph Minter, Head of Research, Technology, MedImmune

  • Chalenges of a good target choice in drug discovery
  • Phenotypic screening to identify a novel Pseudomonas taget Psl
  • combination with PcrV antibody to create a potent bispecific
  • Characterisation of the bispecific antibody in preclinical disease models
  • 14:50 Afternoon Tea

    15:20 Fungi: the unknown superbug

    Chris Longshaw

    Chris Longshaw, Associate Director, Microbiology, Astellas Pharma Europe

  • The threat of antifungal drug resistance
  • opening new doors to diagnosis
  • Preventing fungal infections and treatment
  • Challenges for the future
  • 16:00 Going forward: alternative models for tackling antimicrobial resistance

    Anthony Coates

    Anthony Coates, Professor of Medical Microbiology, St George's Hospital Medical School

  • European antibiotic recovery plan
  • Limited population antimicrobial drug pathway
  • Focus grants on antibiotic discovery and development
  • Global solutions
  • 16:40 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Chris Hoyle

    Chris Hoyle

    Economist, Office for Health Economics
    Chris Longshaw

    Chris Longshaw

    Associate Director, Microbiology, Astellas Pharma Europe
    James Anderson

    James Anderson

    European Partnerships Director, GSK
    Joseph Larsen

    Joseph Larsen

    Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority
    Malcolm Page

    Malcolm Page

    Head of Biology, Basilea Pharmaceutica Ltd
    Michael Mourez

    Michael Mourez

    Therapeutic Area Leader, Sanofi-Aventis
    Pierre  Raboisson

    Pierre Raboisson

    Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development
    Ralph Minter

    Ralph Minter

    Head of Research, Technology, MedImmune
    Richard Bax

    Richard Bax

    Senior Partner, TranScrip Partners

    Anthony Coates

    Professor of Medical Microbiology, St George's Hospital Medical School
    Anthony Coates

    Chris Hoyle

    Economist, Office for Health Economics
    Chris Hoyle

    Chris Longshaw

    Associate Director, Microbiology, Astellas Pharma Europe
    Chris Longshaw

    Daniel Obrecht

    CSO and Co-Founder, Polyphor Ltd
    Daniel Obrecht

    James Anderson

    European Partnerships Director, GSK
    James Anderson

    Joseph Larsen

    Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority
    Joseph Larsen

    Klaus Brandenburg

    CSO and Senior Scientist, Brandenburg Antiinfektiva GmbH and Forschungszentrum Borstel
    Klaus Brandenburg

    Line Matthiessen

    Head of Infectious Diseases and Public Health Unit, European Commision
    Line Matthiessen

    Malcolm Page

    Head of Biology, Basilea Pharmaceutica Ltd
    Malcolm Page

    Michael McArthur

    Chief Scientific Officer, Procarta Biosystems Ltd.
    Michael McArthur

    Michael Mourez

    Therapeutic Area Leader, Sanofi-Aventis
    Michael Mourez

    Pierre Raboisson

    Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development
    Pierre  Raboisson

    Ralph Minter

    Head of Research, Technology, MedImmune
    Ralph Minter

    Richard Bax

    Senior Partner, TranScrip Partners
    Richard Bax

    Richard Vickers

    Associate Director, R&D, Summit
    Richard Vickers

    William Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center
    William Weiss

    Workshops

    Emergence of antimicrobial resistance in 2014 and how stop it
    Workshop

    Emergence of antimicrobial resistance in 2014 and how stop it

    Holiday Inn Regents Park
    4th March 2014
    London, United Kingdom

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.